stockrow
Friday 6 November 2026
Export MRNA’s income statement to Excel — free account
Moderna, Inc.
MRNA Healthcare Biotechnology
Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.
- Revenue
- +2.11%
- EPS
- +7.51%
- Free cash flow
- +38.9%
- Total debt
- +1,765.6%
Quarter to June 2026, against a year earlier
262.61
21.15
+8.76%
Follow MRNA
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | 4 | 5 | 6 | 4 | 2 | 2 | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 8.47 | 8.39 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
5.90 | 4.93 | 6.28 | 3.66 | 5.54 | 49.57 | 107.91 | 9.17 | 0.00 | 0.00 |
Altman Z-Score |
2.46 | 3.76 | 6.11 | 9.64 | 9.27 | 4.65 | 7.70 | 1.20 | — | — |
Altman Z″-Score (non-manufacturers) |
5.12 | 6.71 | 6.65 | 9.90 | 8.20 | 0.57 | 1.67 | 5.11 | (0.31) | 2.18 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 15.39 | 7.68 | 20.32 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
12.34 | 19.35 | 69.09 | 42.43 | 30.92 | 31.49 | (65.36) | (13.61) | (15.37) | (15.37) |
Beneish M-Score |
(3.52) | (3.10) | (2.58) | (2.12) | 17.14 | 22.26 | (3.15) | (2.73) | (1.92) | — |
P/B ratio |
1.33 | 1.46 | 3.10 | 3.69 | 7.24 | 15.54 | 5.51 | 0.81 | 0.00 | 0.00 |
Price to Tangible BV |
1.33 | 1.46 | 3.10 | 3.69 | 7.24 | 15.54 | 5.51 | 0.81 | 0.00 | 0.00 |
EV/Sales |
3.23 | 2.78 | 5.10 | 3.19 | 4.99 | 43.97 | 90.15 | (2.10) | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 6.28 | 6.79 | 0.00 | 0.00 | 0.73 | 0.00 | 0.00 |
EV/Operating CF |
(3.35) | (2.99) | (11.21) | 12.35 | 6.77 | 17.42 | (11.78) | 0.86 | (0.83) | (0.83) |
EV/FCF |
(3.03) | (2.21) | (9.14) | 13.43 | 6.92 | 18.02 | (11.02) | 0.65 | (0.66) | (0.66) |
Quick Ratio |
3.01 | 3.35 | 3.15 | 2.29 | 1.52 | 1.37 | 7.75 | 6.89 | 4.02 | 6.58 |
Current Ratio |
3.29 | 3.67 | 3.42 | 2.73 | 1.76 | 1.44 | 7.89 | 7.02 | 4.09 | 6.68 |
Net Debt/EBITDA |
1.77 | 1.81 | 2.18 | (0.92) | (0.75) | 6.23 | 2.05 | 3.82 | 2.99 | 5.07 |
Debt/Assets |
4.94% | 0.28% | 3.12% | 3.53% | 2.43% | 1.50% | 2.43% | 1.68% | 1.48% | 0.92% |
Debt/Equity |
0.07 | 0.00 | 0.04 | 0.05 | 0.04 | 0.04 | 0.03 | 0.02 | (0.03) | (0.04) |
Asset Turnover |
0.15 | 0.20 | 0.31 | 0.76 | 1.15 | 0.18 | 0.03 | 0.09 | 0.16 | 0.09 |
Operating CF/Net income |
0.66 | 0.84 | 0.66 | 0.60 | 1.12 | (2.71) | 0.89 | 0.82 | 1.23 | (0.29) |
Capex/Depreciation |
(1.36) | (11.18) | (1.26) | (1.06) | (0.99) | (1.66) | (1.19) | (4.60) | (2.70) | (1.88) |
| (28.87%) | (28.77%) | (28.59%) | 50.27% | 146.08% | (39.99%) | (38.00%) | (82.11%) | 60.90% | 52.00% | |
| (21.31%) | (21.87%) | (21.29%) | 33.10% | 76.25% | (16.74%) | (28.94%) | (26.38%) | (21.57%) | (18.42%) | |
ROIC |
(55.51%) | (62.98%) | (45.48%) | 58.10% | 206.87% | 0.00% | (311.74%) | (626.63%) | 0.00% | 0.00% |
Return on Tangible Assets |
(42.18%) | (44.02%) | (50.93%) | 79.44% | 149.10% | (33.86%) | (43.30%) | (25.89%) | (36.92%) | (22.90%) |
Average Days of Receivables |
34.55 | 40.38 | 47.54 | 26.24 | 62.74 | 632.27 | 32.66 | 34.01 | 23.79 | 45.54 |
Research and Development Expense of Revenue |
161.11% | 140.39% | 70.75% | 17.11% | 10.78% | 170.61% | 826.67% | 336.19% | 199.42% | 253.44% |
Selling, General and Administrative Expense of Revenue |
52.37% | 36.28% | 22.62% | 5.88% | 3.07% | 23.41% | 183.33% | 69.78% | 31.45% | 53.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
24.85% | 13.26% | 4.45% | 1.17% | 0.77% | 11.58% | 135.00% | 53.72% | 19.46% | 36.31% |
Graham Net Nets |
0.25 | 0.30 | 0.13 | 0.09 | 0.05 | 0.04 | 0.11 | 0.91 | 0.64 | 0.64 |
Graham Number |
0.00 | 0.00 | 0.00 | 151.90 | 154.64 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(24.65%) | (22.32%) | (11.00%) | 11.81% | 11.92% | (1.86%) | (7.92%) | (31.06%) | (14.03%) | (14.03%) |
Free Cash Flow Yield |
(18.09%) | (25.40%) | (8.90%) | 6.50% | 13.03% | 4.92% | (7.58%) | (35.25%) | (58.55%) | (58.55%) |
Revenue per Share |
5.00 | 8.43 | 17.93 | 48.89 | 45.83 | 2.11 | 0.18 | 1.67 | 3.19 | 1.78 |
Operating CF per Share |
(4.81) | (7.82) | (8.16) | 12.64 | 33.80 | 5.32 | (1.39) | (4.08) | (5.14) | 1.10 |
Capex per Share |
(0.52) | (2.74) | (1.85) | (1.02) | (0.70) | (0.18) | (0.10) | (1.30) | (0.91) | (0.55) |
Free Cash Flow per Share |
(5.33) | (10.56) | (10.01) | 11.63 | 33.09 | 5.14 | (1.48) | (5.38) | (6.04) | 0.55 |
Cash per Share |
14.91 | 18.29 | 22.52 | 25.13 | 26.62 | 12.09 | 3.34 | 18.76 | 11.74 | 17.42 |
Shareholders Equity per Share |
22.24 | 28.39 | 36.27 | 48.54 | 35.10 | 6.72 | 3.55 | 18.87 | (8.55) | (5.51) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
22.24 | 28.39 | 36.27 | 48.54 | 35.10 | 6.72 | 3.55 | 18.87 | (8.55) | (5.51) |
Free Cash Flow |
(2,075.00) | (4,055.00) | (3,825.00) | 4,581.00 | 13,336.00 | 1,959.00 | (491.00) | (436.63) | (389.88) | 33.59 |
Working Capital |
4,557.00 | 5,893.00 | 7,310.00 | 8,508.00 | 6,943.00 | 1,909.00 | 985.69 | 1,340.20 | 591.76 | 924.35 |
Capital Expenditures |
(202.00) | (1,051.00) | (707.00) | (400.00) | (284.00) | (68.00) | (32.00) | (105.77) | (58.40) | (33.14) |
Net Current Asset Value |
2,856.00 | 4,858.00 | 5,753.00 | 6,696.00 | 5,547.00 | 1,522.00 | 714.19 | 1,131.10 | (852.63) | (664.82) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 6.53 | 6.94 | 0.00 | 0.00 | 0.69 | 0.00 | 0.00 |
Capex to Sales |
0.10 | 0.32 | 0.10 | 0.02 | 0.02 | 0.08 | 0.53 | 0.78 | 0.28 | 0.31 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 7.49 | 7.70 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.07 | 0.04 | 0.29 | 0.19 | 0.23 | 0.14 | 0.13 | 0.11 | 0.16 | 0.22 |
Cash ROIC |
(13.78%) | (22.57%) | (16.61%) | 15.30% | 52.36% | 26.91% | (21.19%) | (14.15%) | (175.93%) | 4.56% |
Accounts Receivable Turnover |
7.17 | 5.18 | 6.01 | 8.45 | 8.09 | 1.15 | 6.68 | 10.39 | 15.28 | 6.88 |
Accounts Payable Turnover |
2.40 | 3.17 | 9.32 | 13.73 | 16.36 | 0.64 | 1.62 | 0.96 | 0.86 | 0.61 |
Inventory Turnover |
6.43 | 9.18 | 8.15 | 4.53 | 3.52 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
133.30 | 100.97 | 40.44 | 32.82 | 42.12 | 821.25 | 83.48 | 455.67 | 360.22 | 679.99 |
Days of Inventory on Hand |
64.34 | 29.17 | 15.71 | 63.96 | 200.98 | 2,144.38 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
271.00 | 625.00 | 1,138.50 | 2,280.00 | 2,283.00 | 698.18 | 8.98 | 13.00 | 13.47 | 15.76 |
Average Payables |
361.00 | 462.50 | 503.50 | 394.50 | 160.00 | 12.55 | 19.15 | 25.97 | 24.44 | 24.58 |
Average Inventory |
135.00 | 159.50 | 575.50 | 1,195.00 | 744.00 | 744.00 | — | — | — | — |
Average Assets |
13,240.00 | 16,284.00 | 22,142.00 | 25,263.50 | 16,003.00 | 4,463.21 | 1,775.79 | 1,523.32 | 1,250.83 | 1,250.58 |
Average Common Equity |
9,775.50 | 12,377.50 | 16,488.50 | 16,634.00 | 8,353.00 | 1,867.91 | 1,352.53 | 489.44 | (443.09) | (442.90) |
Columns are period end dates